News und Analysen
![Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses
Regulatory News:
Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s (Paris:TNG) proprietary DuckCelt®-T17 cell line.
![Savara to Report First Quarter 2020 Financial Results and Provide Business Update](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Savara to Report First Quarter 2020 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020
![Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will
![Illumina Reports Financial Results for First Quarter of Fiscal Year 2020](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.
First quarter 2020 results:
-
Revenue of $859 million, a 2% increase compared to
![Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs and digital therapeutics, have
![NANOBIOTIX Announces First Quarter 2020 Revenues](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
NANOBIOTIX Announces First Quarter 2020 Revenues
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of
![Premier Inc. Data: As COVID-19 Cases Spike, Demand for Drugs Used to Treat Related, Co-Morbid Conditions Also Soars](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Premier Inc. Data: As COVID-19 Cases Spike, Demand for Drugs Used to Treat Related, Co-Morbid Conditions Also Soars
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released new data finding that as COVID-19 cases peak, so does demand for drugs used to treat cardiovascular conditions
![QIAGEN posts IFRS Annual Report for 2019 results and 2019 Annual Report on its website](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
QIAGEN posts IFRS Annual Report for 2019 results and 2019 Annual Report on its website
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has posted its Annual Report prepared in accordance with IFRS accounting standards for the year ended December 31, 2019 on
![Bayer – ein langfristiger Kaufkandidat: Börse ist Psychologie!](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Bayer – ein langfristiger Kaufkandidat: Börse ist Psychologie!
Noch vor einem Jahr war die Aktie von Bayer (WKN: BAY001) das große Thema unter den Anlegern. Grund hierfür waren immer neue Hiobsbotschaften im Zuge der Übernahme von Monsanto.
Denn eines der
![Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative
![Novocure Reports First Quarter 2020 Financial Results and Provides Company Update](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Novocure Reports First Quarter 2020 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2020, highlighting revenue growth and financial strength, clinical pipeline developments and the company’s
![Humana Foundation Commits $50M to Coronavirus Relief and Recovery Efforts](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Humana Foundation Commits $50M to Coronavirus Relief and Recovery Efforts
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), today announced it will deploy $50 million in immediate short-term and long-term relief and partner with national and community
![Quidel to Present Virtually at the BofA Securities 2020 Health Care Conference](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Quidel to Present Virtually at the BofA Securities 2020 Health Care Conference
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the
![Clovis Oncology to Present at the Bank of America Health Care Conference 2020](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology to Present at the Bank of America Health Care Conference 2020
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday
![Veeva Announces New Application to Simplify Global Postmarket Surveillance in Medical Device and Diagnostics](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Veeva Announces New Application to Simplify Global Postmarket Surveillance in Medical Device and Diagnostics
Veeva Systems (NYSE: VEEV) today announced Veeva Vault Product Surveillance, a new cloud application for medical device and diagnostics to simplify and standardize the postmarket surveillance
![Veeva to Deliver End-to-End Safety Signal and Risk Management](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Veeva to Deliver End-to-End Safety Signal and Risk Management
Veeva Systems (NYSE: VEEV) today announced Veeva Vault Signal, the industry’s first solution that seamlessly manages signals from identification through risk evaluation and mitigation. Vault Signal
![Veeva CRM Now Integrated with Crossix DIFA Marketing Analytics](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Veeva CRM Now Integrated with Crossix DIFA Marketing Analytics
Veeva today announced Veeva CRM Boost for DIFA, which will bring Veeva CRM field activity data into the Crossix DIFA marketing analytics platform starting in Q3 2020. The new offering is free to
![Spende von Illumina erweitert die Ressourcen des Africa Centre for Disease Control and Prevention für die auf Sequenzierung basierende COVID-19-Kontrolle](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Spende von Illumina erweitert die Ressourcen des Africa Centre for Disease Control and Prevention für die auf Sequenzierung basierende COVID-19-Kontrolle
Illumina, Inc. (NASDAQ: ILMN) freut sich, bekanntgeben zu dürfen, dass die Kommission der Afrikanischen Union im Namen des Africa Center for Disease Control and Prevention (CDC)
![LivaNova Reports First Quarter 2020 Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
LivaNova Reports First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020.
For the first quarter of 2020, worldwide sales
![Formycon: Neues Corona-Medikament im Visier!](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Formycon: Neues Corona-Medikament im Visier!
Formycon (WKN: A1EWVY) stellt sich der Herausforderung der Dekade: Die Münchner Biosimilar-Schmiede nimmt den Kampf gegen COVID-19 auf. Die langjährige Expertise seiner Mediziner ermögliche eine
![Lysogene Reports Its Cash Position as of 31 March 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Lysogene Reports Its Cash Position as of 31 March 2020
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports its cash position as of 31 March
![Sensorion Announces It Will Hold Its General Assembly on May 20, 2020 Behind Closed Doors Alongside the Publication of Its 2019 Annual Financial Report](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sensorion Announces It Will Hold Its General Assembly on May 20, 2020 Behind Closed Doors Alongside the Publication of Its 2019 Annual Financial Report
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company that specializes in the development of novel therapies to restore, treat and prevent
![Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of
![Chemed Reports First-Quarter 2020 Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Chemed Reports First-Quarter 2020 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
![Dexcom Reports First Quarter 2020 Financial Results](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Dexcom Reports First Quarter 2020 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2020.
First Quarter 2020 and COVID-19 Pandemic Response Highlights:
-
Revenue grew 44%